Bronchogen
Not FDA approvedSynthetic short peptide bioregulator
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Bronchogen is a synthetic tetrapeptide (reported sequence Ala-Glu-Asp-Leu) from the Russian peptide bioregulator research program associated with Vladimir Khavinson. It is proposed to act on gene expression in bronchial and lung tissue, with claims that it supports airway lining cell function, though this mechanism is not well established.
What the evidence shows
Evidence comes mostly from a small body of lab and animal studies, largely from one research group, plus one registered human trial with no clear phase listed. It is not approved anywhere by the FDA, and there is no conclusive human evidence that it improves lung or airway health.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.